Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Berchuck

Showing results (111-120 of 372) with videos related to

Pageof 38
Sort By:
Gynecologic Oncology|March 19, 2019
A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgeryCatherine H Watson, Micael Lopez-Acevedo, Gloria Broadwater, et al.
International Journal of Cancer|July 31, 2009
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancerPaula S Lee, Vanessa S Teaberry, Amy E Bland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2012
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancerAngeles Alvarez Secord, Deanna K Teoh, William T Barry, et al.
Gynecologic Oncology|January 7, 2011
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsDeanna Teoh, Tina A Ayeni, Jennifer M Rubatt, et al.
Gynecologic Oncology|April 3, 2007
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinomaLouis A Dainty, John I Risinger, Carl Morrison, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2007
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancerJoellen M Schildkraut, Susan K Murphy, Rachel T Palmieri, et al.
Gynecologic Oncology|June 6, 2021
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, CanadaGillian E Hanley, Paramdeep Kaur, Andrew Berchuck, et al.
Virchows Archiv : an International Journal of Pathology|July 12, 2002
Cell proliferation and apoptosis in human uterine leiomyomas and myometriaDarlene Dixon, Gordon P Flake, Alicia B Moore, et al.
Gynecologic Oncology|December 31, 2002
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancerLaura J Havrilesky, Angeles A Alvarez, Robyn A Sayer, et al.
BMC Cancer|May 28, 2010
Expression signatures of TP53 mutations in serous ovarian cancersMarcus Q Bernardini, Tsukasa Baba, Paula S Lee, et al.
Pageof 38

Showing results (111-120 of 372) with videos related to

Sort By:
Pageof 38
Gynecologic Oncology|March 19, 2019
A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgeryCatherine H Watson, Micael Lopez-Acevedo, Gloria Broadwater, et al.
International Journal of Cancer|July 31, 2009
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancerPaula S Lee, Vanessa S Teaberry, Amy E Bland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2012
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancerAngeles Alvarez Secord, Deanna K Teoh, William T Barry, et al.
Gynecologic Oncology|January 7, 2011
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsDeanna Teoh, Tina A Ayeni, Jennifer M Rubatt, et al.
Gynecologic Oncology|April 3, 2007
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinomaLouis A Dainty, John I Risinger, Carl Morrison, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2007
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancerJoellen M Schildkraut, Susan K Murphy, Rachel T Palmieri, et al.
Gynecologic Oncology|June 6, 2021
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, CanadaGillian E Hanley, Paramdeep Kaur, Andrew Berchuck, et al.
Virchows Archiv : an International Journal of Pathology|July 12, 2002
Cell proliferation and apoptosis in human uterine leiomyomas and myometriaDarlene Dixon, Gordon P Flake, Alicia B Moore, et al.
Gynecologic Oncology|December 31, 2002
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancerLaura J Havrilesky, Angeles A Alvarez, Robyn A Sayer, et al.
BMC Cancer|May 28, 2010
Expression signatures of TP53 mutations in serous ovarian cancersMarcus Q Bernardini, Tsukasa Baba, Paula S Lee, et al.
Pageof 38